Summit Therapeutics Inc.
WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
FIGI: BBG00X3GQL76
SMMT
Summit Therapeutics Inc.
GICS: -
·
Sektor: Healthcare
·
Sub-Sektor: Biotechnology
NAME
Summit Therapeutics Inc.
ISIN
US86627T1088
TICKER
SMMT
MIC
XNAS
REUTERS
SMMT.OQ
BLOOMBERG
SMMT US
Financial Intelligence
FÜR INVESTOREN
FÜR TRADER
Börsenhandel
Warrants
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von BusinessWire bereitgestellt.
Do., 16.01.2025
Summit Therapeutics
US86627T1088
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 145,550 shares of common stock. Awards were made to nine new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees...
Summit Therapeutics
Di., 07.01.2025
Summit Therapeutics
US86627T1088
Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Monday, January 13, 2025 at 3:00 PM PT. Robert W. Duggan, Chairman and Chief Executive Officer, and Dr. Maky Zanganeh, Chief Executi...
Summit Therapeutics
Fr., 13.12.2024
Summit Therapeutics
US86627T1088
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 98,000 shares of common stock. Awards were made to six new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees o...
Summit Therapeutics
Di., 26.11.2024
Summit Therapeutics
US86627T1088
Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the 7th Annual Evercore HealthCONx Conference and Citi’s 2024 Global Healthcare Conference, both being held in Miami. Our management team will participate in fireside chats surrounding the development of our innovat...
Summit Therapeutics
Do., 21.11.2024
Summit Therapeutics
US86627T1088
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 227,600 shares of common stock. Awards were made to 15 new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees o...
Summit Therapeutics
Mi., 30.10.2024
Summit Therapeutics
US86627T1088
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reported an update on its operational progress and financial results for the third quarter and nine months ended September 30, 2024.
Operational & Corporate Updates
Our operational progress continues with ivonescimab (SMT112), an investigational, potentially fir...
Summit Therapeutics
Mi., 23.10.2024
Summit Therapeutics
US86627T1088
Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its third quarter 2024 financial results and provide an operational update for the Company on Wednesday, October 30, 2024, before the market opens.
Summit will host a live webcast of the earnings conference call at 9:00am ET, which wi...
Summit Therapeutics
Fr., 04.10.2024
Summit Therapeutics
US86627T1088
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 249,550 shares of common stock. Awards were made to ten new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees ...
Summit Therapeutics
Do., 03.10.2024
Summit Therapeutics
US86627T1088
Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that we have completed enrollment in our HARMONi clinical trial, a multi-regional Phase III study sponsored by Summit evaluating ivonescimab plus platinum-doublet chemotherapy vs. placebo plus platinum-doublet chemotherapy with epidermal growth factor recept...
Summit Therapeutics
Mo., 16.09.2024
Summit Therapeutics
US86627T1088
Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that data for the novel, potential first-in-class investigational bispecific antibody, ivonescimab, was presented at the 2024 European Society for Medical Oncology Annual Meeting (ESMO 2024) in Barcelona, Spain, including two presentations and one poster fea...
Summit Therapeutics
Informationen zu Product Placements
SMART * AD
P R O D U C T S U G G E S T I O N S
